

PARTICIPATING FACULTY

The Hidden Condition: Status, Challenges, and Opportunities in the Management of Enlarged Prostate for Managed Care

This supplement to *The American Journal of Managed Care* contains information on the clinical and economic issues associated with the treatment of enlarged prostate. This supplement has been peer reviewed by experts in the field.

Faculty

Libby Black, PharmD

Manager
Global Health Outcomes
GlaxoSmithKline
Research Triangle Park,
North Carolina

Evelyn Chiao, PharmD

Analyst and Outcomes Research
Fellow
Applied Health Outcomes
Palm Harbor, Florida

E. Anne Davis, PharmD, MS

Manager, Global Health Outcomes
GlaxoSmithKline
Research Triangle Park,
North Carolina

Michael T. Eaddy, PharmD, PhD

Director
Applied Health Outcomes
Palm Harbor, Florida

Thomas C. Fenter, MD

Assistant Professor of Urology
University of Mississippi
Medical Center
Corporate Medical Advisor
Blue Cross & Blue Shield
of Mississippi
Jackson, Mississippi

Thomas D. Gilbert, Jr, MS

Ipsen Pharmaceuticals
Milford, Massachusetts
(employed by PharMetrics at
the time of these analyses)

Amy L. Grogg, PharmD

Vice President
Applied Health Outcomes
Palm Harbor, Florida

Muta M. Issa, MD, MBA

Associate Professor of Urology
Emory University School
of Medicine
Chief of Urology
Atlanta VA Medical Center
Atlanta, Georgia

Eric J. Kruep, PharmD, MS

Analyst
Applied Health Outcomes
Palm Harbor, Florida

Michael James Naslund, MD, MBA

Professor of Urology
University of Maryland School
of Medicine
Director
Maryland Prostate Center
Baltimore, Maryland

Daniel A. Ollendorf, MPH

Vice President, Applied Research
and Public Policy
PharMetrics, Inc
Watertown, Massachusetts

Manan B. Shah, PharmD, PhD

Assistant Director
Applied Health Outcomes
Palm Harbor, Florida

Faculty Disclosures

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

■ **Libby Black, PharmD**

Employee of:
GlaxoSmithKline

■ **E. Anne Davis, PharmD, MS**

Employee of:
GlaxoSmithKline

■ **Thomas C. Fenter, MD**

Speakers' bureau for:
Bayer Healthcare
GlaxoSmithKline
Schering-Plough

■ **Muta M. Issa, MD, MBA**

Consultant to:
Cytogen
Dialog Medical
GlaxoSmithKline
Johnson & Johnson
Novartis
Sanofi-Aventis

■ **Michael James Naslund, MD, MBA**

Consultant to:
Celsion
Speakers' bureau/advisory board for:
The Center for Medical Knowledge
GlaxoSmithKline
Sanofi-Aventis
Speakers' bureau for:
Boehringer Ingelheim
Merck

■ **Daniel A. Ollendorf, MPH**

Research grant:
GlaxoSmithKline

Thomas D. Gilbert, Jr, MS, reports no relevant relationships with pharmaceutical companies.

GlaxoSmithKline provided funding to Applied Health Outcomes to perform research and development related to this manuscript. The following authors are employed by Applied Health Outcomes, which receives grant support from GlaxoSmithKline and other pharmaceutical companies:

■ **Evelyn Chiao, PharmD**

■ **Michael T. Eaddy, PharmD, PhD**

■ **Amy L. Grogg, PharmD**

■ **Eric J. Kruep, PharmD, MS**

■ **Manan B. Shah, PharmD, PhD**

Signed disclosures are on file at the offices of *The American Journal of Managed Care*, Jamesburg, New Jersey.

*The Hidden Condition:
Status, Challenges, and Opportunities
in the Management of Enlarged Prostate for Managed Care*

This supplement has been supported by funding from **GlaxoSmithKline**.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.